CVS Health announced Wednesday, November 4, 2026, that it will break up its one-hundred-seventeen-billion-dollar business, separating its nine thousand retail pharmacies from the Aetna insurance division and Caremark pharmacy benefit manager. The split, planned for completion by the first half of 2028, marks the end of one of the most ambitious vertical integration experiments in American healthcare—and a tacit admission that bigger isn't always better.

The company will divide into two publicly traded entities: CVS Pharmacy, which will include the retail pharmacies, in-store clinics, and mail-order prescription business, and a second company housing Aetna and Caremark. The decision comes after years of regulatory scrutiny, Medicare payment pressures, and mounting questions from investors about whether the integrated model was delivering the promised synergies.

Why the Integrated Model Failed

When CVS acquired Aetna for seventy-eight billion dollars in 2018, the pitch was simple: combine a retail pharmacy chain with an insurance company and a pharmacy benefit manager to control healthcare costs, improve patient outcomes, and capture value at every step of the prescription journey. Eight years later, the reality has been far messier.

Reuters reported that the split represents a "major unwinding" of the integrated healthcare model CVS championed. The company faced persistent accusations of conflicts of interest—critics argued that owning both the insurer and the pharmacy created incentives to steer patients toward CVS stores and away from competitors, even when it wasn't in the patient's best interest.

Regulatory pressure intensified in recent years as lawmakers scrutinized pharmacy benefit managers for driving up drug costs while pocketing rebates. Caremark, one of the nation's three largest PBMs, became a frequent target. By splitting off the pharmacy business, CVS can reduce the perceived conflicts and insulate its insurance operations from the political heat surrounding PBMs.

What the Breakup Means for Pharmacies and Patients

The new CVS Pharmacy entity will operate the nine thousand retail locations, in-store MinuteClinic urgent care centers, and the mail-order prescription business that serves millions of Americans. The Guardian noted that the standalone pharmacy company will be free to pursue partnerships with competing insurers and PBMs—something that was awkward when Aetna and Caremark were under the same corporate umbrella.

For patients, the breakup could mean more competitive pricing and fewer concerns about being locked into a CVS-controlled ecosystem. Independent pharmacy advocates have long argued that CVS's vertical integration squeezed out smaller competitors and limited patient choice. A standalone CVS Pharmacy will still be a retail giant, but it will face pressure to compete on service and price rather than relying on captive Aetna and Caremark customers.

Aetna and Caremark: The Insurance Side of the Split

The second company—which has not yet been named—will house Aetna, one of the nation's largest health insurers, and Caremark, the pharmacy benefit manager that negotiates drug prices and manages prescription benefits for employers and health plans. CNBC reported that CVS executives believe separating the insurance and PBM operations from the pharmacy business will unlock shareholder value and allow each entity to focus on its core competencies.

The New York Times described the split as CVS "ending the healthcare integration" experiment, a recognition that the promised efficiencies never materialized at the scale needed to justify the regulatory and reputational costs. Aetna will now compete more directly with UnitedHealth Group and Anthem without the baggage of conflicts tied to CVS retail pharmacies.

The Larger Trend: Big Healthcare Bets Are Being Unwound

CVS's breakup is part of a broader retreat from vertical integration in healthcare. Walgreens Boots Alliance has struggled with its own clinic experiments, and Amazon's foray into primary care through One Medical has yet to prove transformative. The lesson from CVS is clear: controlling every link in the healthcare chain sounds good in a PowerPoint deck, but executing it profitably while navigating regulatory scrutiny and maintaining patient trust is far harder.

The split is expected to be completed by the first half of 2028, giving both entities time to establish independent management teams, separate financial reporting, and negotiate new contracts. CVS Health will remain the parent until the breakup is finalized, but Wednesday's announcement makes it official—the grand healthcare integration experiment is over, and the industry is watching to see if two smaller, focused companies can deliver what one giant conglomerate could not.